Newsletter
Novo Nordisk India has partnered with Emcure Pharmaceuticals to launch Poviztra®, a new brand of its weight-loss drug Wegovy®, aiming to make obesity treatment more widely available. The stock gained more than 8% intraday following the update.
Poviztra® will serve as the second brand of Wegovy®, which Novo Nordisk launched in India in June 2025.
What’s going on: under the deal, Emcure will handle how Poviztra® is marketed and sold across India. The medicine uses semaglutide, a drug that helps people lose weight by controlling appetite and calorie intake.
With this partnership, Emcure becomes the first Indian company allowed to sell semaglutide for long-term weight management.
Why they’re a good fit: Novo Nordisk brings global expertise in GLP-1 therapies and clinical research, while Emcure offers a strong on-ground distribution network and deep understanding of India’s healthcare landscape.
Together, they aim to make cutting-edge obesity treatments more accessible and affordable for Indian patients.
